Welcome to our dedicated page for Owlet news (Ticker: OWLT), a resource for investors and traders seeking the latest updates and insights on Owlet stock.
Owlet, Inc. (NYSE: OWLT) is a pediatric health platform known for smart infant monitoring devices, pediatric wearables, and connected nursery technology. The OWLT news feed on Stock Titan aggregates company announcements, press releases, and market updates so readers can follow how Owlet’s products, partnerships, and financial performance evolve over time.
News about Owlet often covers product launches and regulatory milestones, such as the TGA‑approved rollout of Dream Sock in Australia and New Zealand, the introduction of the Owlet360 subscription service in markets like the UK and Ireland, and cybersecurity certifications for the Dream Sight camera. Articles also highlight collaborations that connect BabySat infant pulse oximeter data into remote patient monitoring platforms and electronic health record workflows through partners including Locus Health and Rhapsody.
Investors and parents can use this page to review updates on Owlet’s DME and insurance‑supported distribution channels, including its partnership with 1 Natural Way, as well as recognition such as inclusion on Fast Company’s Brands That Matter list. The feed also captures earnings releases, guidance updates, and SEC‑related communications that reflect Owlet’s positioning as a small‑cap healthcare growth equity company in the digital health and medical device space.
By checking this OWLT news page regularly, readers can track developments in Owlet’s pediatric wearables, subscription services like Owlet360, international expansion, clinical integrations, and corporate actions that may influence the outlook for Owlet stock and its role in connected infant care.
Owlet, a leader in smart infant monitoring, has achieved UKCA certification for its Dream Sock, a significant milestone following its recent CE Mark certification. This recognition allows Owlet to expand its reach across the UK and Europe, where it already has key retail partnerships. The Dream Sock, designed for healthy infants, measures oxygen saturation, pulse rate, and provides sleep insights. It will soon be available at major retailers in the UK, Germany, and France, and later in other European countries. This expansion is poised to impact over 3.8 million annual births in the region.
Owlet, Inc. announced strong first quarter 2024 results with revenue of approximately $14.8 million, up 37% year over year, gross margin at 44.4%, and net income of $3.3 million. The company's adjusted EBITDA loss improved by 46% year over year. Owlet's CEO highlighted the positive feedback on their medical devices and increased demand for their products, projecting continued success in 2024.
Owlet, Inc. announces the EU medical device certification of Dream Sock, a smart infant monitoring product. This certification allows Owlet to expand its product portfolio in European markets and provide caregivers with innovative technology for home-based baby monitoring. The product offers clinically-proven accuracy and real-time data delivery through a mobile app and Base Station. Dream Sock is set to launch in Germany, France, and the UK this spring, with plans for further European expansion.
Owlet, Inc. (NYSE: OWLT), a leader in smart infant monitoring, will be participating in two upcoming investor conferences: the Emerging Growth Virtual Conference on May 8, 2024, and the Sidoti May Micro Cap Virtual Conference on May 8-9, 2024. The Company's Co-Founder and CEO, Kurt Workman, along with CFO Kate Scolnick, will present at both events.
Owlet, Inc. will announce its first quarter 2024 financial results on May 6, 2024. The company's executives will host a conference call to discuss the results and provide a business update.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.